Add Company
Join Now

invIOs INNOVATIVE IMMUNO-ONCOLOGY Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Employee Data

  • invIOs INNOVATIVE IMMUNO-ONCOLOGY has 24 Employees.(i)
  • invIOs INNOVATIVE IMMUNO-ONCOLOGY grew their employee count by -20% last year.

invIOs INNOVATIVE IMMUNO-ONCOLOGY's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M15-32%N/AN/A
#10
$10.1M48-9%N/AN/A
Add Company

What Is invIOs INNOVATIVE IMMUNO-ONCOLOGY?

invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the biotechnology value chain, with in-house expertise in R&D, clinical development, CMC, IP, scouting and more. All of our approaches are designed with a single goal: To transform patients' lives, so that cancer doesn’t.

keywords:N/A

N/A

Total Funding

24

Number of Employees

N/A

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.2M240%N/A
#2
$2.4M24N/AN/A
#3
$2.4M24N/AN/A
#4
$2.4M24N/AN/A
#5
$2.4M24N/AN/A